In the News: January 26-February 1

Sg2 is dedicated to helping our clients interpret the latest news and trends in health care. Below you’ll find our analysis of this week’s key industry headlines, along with links to related Sg2 resources.

Alzheimer Disease in 2017: Maintaining Hope After Disappointment

A recent article in Kaiser Health News addresses the status quo of our nation’s sixth-leading cause of death: Alzheimer disease. With the latest disappointing results from Eli Lilly’s phase 3 clinical trial for solanezumab, the scientific community has suffered a major setback. Historically, however, clinical trials for neurodegenerative disease have had a 99% failure rate with no luck in producing a single drug that successfully treats Alzheimer disease. Current therapies for Alzheimer disease only treat the disease’s symptoms. The future of Alzheimer disease has never looked so disheartening, as the latest research predicts that with the aging baby boomer population, disease incidence will grow from 5 million today to 14 million in 2050.

Sg2 experts have extensively covered Alzheimer disease and have explored innovative interventions in this space:

  • To view Sg2’s infographic on Innovations in Alzheimer Disease and Dementia Care, click here.
  • To learn more and to review Sg2’s 10-year forecast for dementia and cognitive disorders, read the Sg2 FAQ: Alzheimer Disease and Dementia Care Landscape.

Health Affairs: Despite Modest Improvements in Experience, No Meaningful Gains From Medicare Incentives

A recent Health Affairs article examines improvements in patient experience in US hospitals and the impact of tying payment to performance under the Value-Based Purchasing (VBP) Program from 2008 to 2014. The authors found that improvements had slowed in recent years, and they did not find evidence that the VBP program had a positive impact on patient experience.

Sg2 experts believe a multipronged approach is needed to improve patient experience. Read the Sg2 FAQ: Measuring and Improving Patient Experience (PDF) to learn about progressive organizations that have begun employing a host of tools and strategies to enhance experience, such as rapid surveys, direct patient engagement tools, proprietary physician ratings websites and chief experience officers.

2017 Consumer Survey Reports Strong Appetite for Virtual Health Visits

A new consumer survey conducted by American Well reports that 20% of patients would leave their health care provider for one that offered virtual health services. Younger people and parents were most likely to leave, citing convenience and lower costs as key draws. Consumers are highly interested in using virtual health for chronic disease management, prescription refills, and caring for an elderly parent or relative.

At Sg2, we believe that many organizations have not yet fully captured the tremendous value of virtual health as part of their enterprise-wide strategy. To move forward with virtual health, explore Sg2’s virtual health resource kit, which includes guiding principles, a strategic action plan and case studies from leading organizations.

  • Share
  • Follow Sg2 on Facebook
  • Follow Sg2 on Twitter
  • Connect with Sg2 on LinkedIn
"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube